SpringWorks Therapeutics Inc. (SWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SpringWorks Therapeutics Inc. Profile
| - Industry | - Sector | Saqib Islam CEO | NASDAQ (NGS) Exchange | 85205L107 CUSIP |
| US Country | 368 Employees | - Last Dividend | - Last Split | 5 Jun 1987 IPO Date |
Overview
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for patients with rare diseases and cancer. Established in 2017 and based in Stamford, Connecticut, SpringWorks Therapeutics aims to address the significant unmet needs of underserved patient populations by bringing innovative treatments to the market. The company has formed strategic collaborations with industry leaders like BeiGene, Ltd., GlaxoSmithKline LLC, Pfizer Inc., as well as with academic institutions such as Katholieke Universiteit Leuven, the Flanders Institute for Biotechnology, and the Dana-Farber Cancer Institute. These partnerships enhance its developmental capacity, enabling a robust pipeline of targeted therapies.
Products and Services
- OGSIVEO (nirogacestat): This is SpringWorks Therapeutics' lead product candidate, an oral small molecule gamma secretase inhibitor. It is currently in a Phase III DeFi trial for the treatment of desmoid tumors, a type of rare, often aggressive tumor that can cause significant morbidity. Additionally, Nirogacestat is under Phase 2 clinical development as a monotherapy for ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
- Mirdametinib: An oral small molecule MEK inhibitor undergoing Phase 2b clinical trials. Mirdametinib targets neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a condition causing tumors along the nerves. The drug is also in Phase 1/2 clinical trial for treating pediatric and young adult patients with low-grade gliomas, in addition to being explored in monotherapy and combination approaches for other genetically defined solid tumors.
- Mirdametinib + Lifirafenib: This combination therapy is in a Phase 1b clinical trial targeting patients with advanced or refractory solid tumors. The collaboration seeks to leverage the synergistic effects of mirdametinib, a MEK inhibitor, and lifirafenib, aiming to offer new horizons in cancer therapy.
- Brimarafenib (BGB-3245): An oral selective small molecule inhibitor designed to target monomeric and dimeric forms of activating BRAF mutations. This product candidate is part of the company's broader strategy to develop targeted oncology therapies.
Contact Information
